US segment drags overall performance
STR reported a lower than expected performance in 2QFY22 due to continued headwinds in the US business. Sales in other regulated markets witnessed...
391 Views
Strides Pharma Science: Unanticipated De-Growth Across Markets..
Strides reported a weak quarter witnessing a de-growth across revenues of 12% YoY to Rs.688cr during Q1FY22 owing to major sector headwinds such as...
228 Views
US/Institutional business drives earnings
STR's 4QFY21 operational performance was marginally below our estimate. The robust performance in the US/Institutional segment within emerging...
319 Views